Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. - Livingstone,P..O..; Adlusi,S..; Helling,F.. (Vaccine, 1994)